SecBot SecBot

NBTX

Nanobiotix S.A.
Nasdaq· Pharmaceutical Preparations· Inc. I0· CIK 0001760854 Biotech & Drug Discovery
$31.53 +2.17 (+7.39%)
Oct 26 4:00 PM ET · prev $29.36
Market cap
$1.5B
Small cap
Median target
🔒 Subscribers only
1 year
+109.1%
from $15.08 · Oct 27
30 days
−3.3%
from $32.60
52-week range
$15.08–55.07
−43% from high · low Oct 27
Avg volume 20D
153.5K
shares / day
Short interest
146.9K
≈0.3% of shares · −16.6%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 1 bearish · 1 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 7/10
Strongest BEARISH Nanobiotix filed its H1 2026 half-year report, showing a net loss of €34.3 million (vs. €5.4 million in H1…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 2 trimmed or exited.

  • Short sellersCOVERING

    Short interest −16.6% to 146.9K shares. 1.0 days to cover, ≈0.3% of shares.

  • TrendDOWNTREND

    5% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD49,789$1.9M
UBS Group AGTRIM2,577$97.2K
RHUMBLINE ADVISERSTRIM1,502$56.6K
MORGAN STANLEYADD36,274$1.1M
UBS Group AGDOUBLED5,557$171.5K
MORGAN STANLEYDOUBLED22,923$530.0K
Optiver Holding B.V.DOUBLED16,225$375.1K
BNP PARIBAS FINANCIAL MARKETSDOUBLED3,600$83.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jun 4, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
May 1, 2026UBS
MAINTAIN
MAINTAINNeutral

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.54-$0.70–-$0.38-316.2%$29.4M
Next FY-$0.15-$0.22–-$0.08+49.1%$44.4M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 24, 2026
Press release
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy…
Oct 20, 2026
Press release
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority...
Oct 1, 2026
Earnings
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical…
Sep 24, 2026
Earnings
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage…
Sep 22, 2026
Activist
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority…

Short side

FINRA· Sep 30, 2026
146,868
shares short
-16.6%
vs prior settlement
1.0
days to cover
≈0.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 24, 2026 Other
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progres
Oct 20, 2026 SEC
Nanobiotix filed a Form 6-K with a press release disclosing its share capital and voting rights as of September 30…
6-K — Impact 1/10
Oct 1, 2026 SEC
Nanobiotix appointed Arnd Christ as CFO effective October 1, 2026, replacing Bart Van Rhijn who stepped down after…
6-K — Impact 2/10
Sep 22, 2026 Press
Nanobiotix S.A. disclosed its monthly share capital and voting rights as of August 31, 2026, reporting 50,941,528…
Impact 1/10
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
49,789 shares ($1.9M)
Jun 30, 2026 Inst.
UBS Group AG — TRIM
2,577 shares ($97.2K)
May 26, 2026 Press
Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants…
Impact 5/10

SecBot reports

14 filings · 11 press releases · 4 bullish · 1 bearish · 9 neutral
All NBTX filing & press-release reports (25)